Ge Long Hui·2025-12-10 02:43Group 1 - The core viewpoint of the article highlights that Fosun Pharma has signed a $2.1 billion collaboration agreement with Pfizer for its preclinical small molecule GLP-1 drug, YP05002, positioning it favorably in the GLP-1 market [1] - The report from Credit Lyonnais indicates that Pfizer's active participation and long-term strategy in the GLP-1 field make the financial terms of the collaboration reasonable compared to similar licensing agreements [1] - Following the renewed market interest in the GLP-1 sector, it is anticipated that Fosun Pharma's stock price will respond positively, although this may increase competitive pressure for domestic peers expanding overseas [1] Group 2 - Credit Lyonnais has raised its profit forecasts for Fosun Pharma, increasing the net profit estimates for 2025 to 2027 by 1%, 2.4%, and 1.9% respectively, reflecting the financial impact of the collaboration [1] - The target price for Fosun Pharma's H-shares has been raised from HKD 29.6 to HKD 31.6, while the target price for A-shares has been increased from CNY 40.2 to CNY 42.4, maintaining an "outperform" rating [1]